An ongoing clinical trial (NCT03546361) is investigating the efficacy of pembrolizumab in combination with AdCCL21-DC in stage IV NSCLC patients who are either EGFR/ALK wild-type after progression on a PD-L1 inhibitor or EGFR/ALK mutant after progression on TKI therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.